Arbutus Biopharma share price today

(ABUS)

Arbutus Biopharma share price is $3.21 & ₹272.77 as on 21 Dec 2024, 2.30 'hrs' IST

$3.21

Market is closed - opens 8 PM, 23 Dec 2024

View live Arbutus Biopharma share price in Dollar and Rupees. Guide to invest in Arbutus Biopharma from India. Also see the sentimental analysis on Indian investors investing in Arbutus Biopharma. Get details on the Indian mutual funds that are investing in Arbutus Biopharma. Get Analyst recommendations and forecasts along with all the Arbutus Biopharma's financials.

Arbutus Biopharma share price movements

Today's Low: $3.17
Today's High: $3.26
$3.21
1.24%
Downside
Day's Volatility :2.61%
Upside
1.38%
52 Weeks Low: $2.21
52 Weeks High: $4.73
$3.21
31.15%
Downside
52 Weeks Volatility :53.23%
Upside
32.06%

Arbutus Biopharma Returns

Period	Arbutus Biopharma Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	-20.54%	-12.2%	0.0%
6 Months	4.56%	-6.9%	0.0%
1 Year	35.44%	2.7%	0.0%
3 Years	-22.84%	-0.2%	-17.3%

Arbutus Biopharma Key Statistics

in dollars & INR

Previous Close	$3.21
Open	$3.18
Today's High	$3.255
Today's Low	$3.1701
Market Capitalization	$604.5M
Today's Volume	$735.4K
52 Week High	$4.725
52 Week Low	$2.21
Revenue TTM	$6.7M
EBITDA	$-77.1M
Earnings Per Share (EPS)	$-0.43
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-67.81%

How to invest in Arbutus Biopharma from India?

It is very easy for Indian residents to invest directly in Arbutus Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arbutus Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Arbutus Biopharma or ABUS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arbutus Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arbutus Biopharma shares which would translate to 0.265 fractional shares of Arbutus Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Arbutus Biopharma, in just a few clicks!

Returns in Arbutus Biopharma for Indian investors in Rupees

Investment Value

₹1,00,000

Arbutus Biopharma investment value today

Current value as on today

₹1,37,538

Returns

₹37,538

(+37.54%)

Returns from Arbutus Biopharma Stock

₹35,443 (+35.44%)

Dollar Returns

₹2,095 (+2.1%)

Indian investors sentiment towards Arbutus Biopharma

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Arbutus Biopharma on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 9% more investors are searching Arbutus Biopharma in the last 30 days versus the previous period.

Global Institutional Holdings in Arbutus Biopharma

Morgan Stanley - Brokerage Accounts
11.46%
Whitefort Capital Management, LP.
6.79%
BlackRock Inc
6.10%
Vanguard Group Inc
4.71%
Two Seas Capital LP
4.43%
State Street Corp
2.33%

Analyst Recommendation on Arbutus Biopharma

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Arbutus Biopharma

What analysts predicted

Upside of 57.29%

Current:

$3.21

Target:

$5.05

Insights on Arbutus Biopharma

Price Movement
In the last 1 year, ABUS stock has moved up by 45.2%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.72M → 1.33M (in $), with an average decrease of 22.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -19.79M → -19.71M (in $), with an average increase of 0.4% per quarter
ABUS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 20.5% return, outperforming this stock by 47.2%

Arbutus Biopharma Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$5.9M	↓ 44.86%
Net Income	$-57.1M	↓ 32.35%
Net Profit Margin	-967.8%	↓ 179.01%

	FY19	Y/Y Change
Revenue	$6.0M	↑ 1.88%
Net Income	$-153.7M	↑ 169.22%
Net Profit Margin	-2.6K%	↓ 1589.56%

	FY20	Y/Y Change
Revenue	$6.9M	↑ 15.02%
Net Income	$-65.2M	↓ 57.58%
Net Profit Margin	-943.17%	↑ 1614.19%

	FY21	Y/Y Change
Revenue	$11.0M	↑ 58.92%
Net Income	$-77.4M	↑ 18.62%
Net Profit Margin	-703.96%	↑ 239.21%

	FY22	Y/Y Change
Revenue	$39.0M	↑ 255.11%
Net Income	$-69.5M	↓ 10.21%
Net Profit Margin	-178.01%	↑ 525.95%

	FY23	Y/Y Change
Revenue	$18.1M	↓ 53.51%
Net Income	$-72.8M	↑ 4.89%
Net Profit Margin	-401.57%	↓ 223.56%

	Q2 FY23	Q/Q Change
Revenue	$4.7M	↓ 30.45%
Net Income	$-17.1M	↑ 10.55%
Net Profit Margin	-367.53%	↓ 136.29%

	Q3 FY23	Q/Q Change
Revenue	$4.7M	↑ 0.15%
Net Income	$-20.1M	↑ 17.61%
Net Profit Margin	-431.6%	↓ 64.07%

	Q4 FY23	Q/Q Change
Revenue	$2.1M	↓ 53.95%
Net Income	$-19.3M	↓ 3.94%
Net Profit Margin	-900.33%	↓ 468.73%

	Q1 FY24	Q/Q Change
Revenue	$1.5M	↓ 28.58%
Net Income	$-17.9M	↓ 7.44%
Net Profit Margin	-1.2K%	↓ 266.45%

	Q2 FY24	Q/Q Change
Revenue	$1.7M	↑ 12.66%
Net Income	$-19.8M	↑ 10.75%
Net Profit Margin	-1.1K%	↑ 19.85%

	Q3 FY24	Q/Q Change
Revenue	$1.3M	↓ 22.42%
Net Income	$-19.7M	↓ 0.4%
Net Profit Margin	-1.5K%	↓ 325.59%

	FY18	Y/Y Change
Profit	$-52.0M	↑ 0.0%

	FY19	Y/Y Change
Profit	$-51.6M	↓ 0.79%

	FY20	Y/Y Change
Profit	$-40.6M	↓ 21.37%

	FY21	Y/Y Change
Profit	$9.2M	↓ 122.76%

	FY22	Y/Y Change
Profit	$37.6M	↑ 307.06%

	FY23	Y/Y Change
Profit	$-55.6M	↓ 247.79%

	Q2 FY23	Q/Q Change
Profit	$4.3M	↓ 32.17%

	Q3 FY23	Q/Q Change
Profit	$4.3M	↓ 0.46%

	Q4 FY23	Q/Q Change
Profit	$1.8M	↓ 58.36%

	Q1 FY24	Q/Q Change
Profit	$1.2M	↓ 34.1%

	Q2 FY24	Q/Q Change
Profit	$1.4M	↑ 16.4%

	Q3 FY24	Q/Q Change
Profit	$1.3M	↓ 2.26%

	FY18	Y/Y Change
Operating Cash Flow	$-67.9M	↑ 39.71%
Investing Cash Flow	$-4.1M	↓ 114.83%
Financing Cash Flow	$55.6M	↑ 12.78%

	FY19	Y/Y Change
Operating Cash Flow	$-71.0M	↑ 4.57%
Investing Cash Flow	$28.3M	↓ 786.65%
Financing Cash Flow	$37.5M	↓ 32.63%

	FY20	Y/Y Change
Operating Cash Flow	$-51.4M	↓ 27.55%
Investing Cash Flow	$-14.9M	↓ 152.61%
Financing Cash Flow	$86.7M	↑ 131.59%

	FY21	Y/Y Change
Operating Cash Flow	$-67.5M	↑ 31.28%
Investing Cash Flow	$-12.7M	↓ 14.96%
Financing Cash Flow	$137.2M	↑ 58.2%

	FY22	Y/Y Change
Operating Cash Flow	$-35.4M	↓ 47.65%
Investing Cash Flow	$-74.9M	↑ 491.12%
Financing Cash Flow	$31.8M	↓ 76.82%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-19.6M	↓ 28.36%
Investing Cash Flow	$1.4M	↓ 91.36%
Financing Cash Flow	$4.7M	↓ 76.77%

Arbutus Biopharma Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Arbutus Biopharma Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arbutus Biopharma Corporation	-6.69%	4.56%	35.44%	-22.84%	16.73%
Regeneron Pharmaceuticals, Inc.	-4.72%	-33.43%	-16.35%	14.7%	89.27%
Biontech Se	9.01%	28.55%	5.71%	-57.13%	220.59%
Alnylam Pharmaceuticals, Inc.	-3.99%	7.16%	25.05%	27.48%	103.59%
Vertex Pharmaceuticals Incorporated	-12.1%	-16.49%	-2.12%	78.05%	80.31%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arbutus Biopharma Corporation	NA	NA	0.0	-0.54	-0.68	-0.33	NA	0.56
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.05	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arbutus Biopharma Corporation	Buy	$604.5M	16.73%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	89.27%	17.67	33.61%
Biontech Se	Buy	$26.8B	220.59%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.7B	103.59%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$115.2B	80.31%	32.84	-4.51%

About Arbutus Biopharma

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Organization	Arbutus Biopharma
Employees	73
CEO	Mr. Michael J. McElhaugh
Industry	Health Technology

Management People of Arbutus Biopharma

Name	Title
Mr. Michael J. McElhaugh	Co-Founder, Interim President, CEO & Director
Dr. Michael J. Sofia Ph.D.	Chief Scientific Officer
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer
Ms. Lisa M. Caperelli	Vice President of Investor Relations
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary
Ms. Shannon Briscoe SPHR	Vice President of Human Resources
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary

Important FAQs about investing in Arbutus Biopharma from India :

What is Arbutus Biopharma share price today?

Arbutus Biopharma share price today stands at $3.21, Open: $3.18 ; Previous Close: $3.21 ; High: $3.26 ; Low: $3.17 ; 52 Week High: $4.73 ; 52 Week Low: $2.21. The stock opens at $3.18, after a previous close of $3.21. The stock reached a daily high of $3.26 and a low of $3.17, with a 52-week high of $4.73 and a 52-week low of $2.21.

Can Indians buy Arbutus Biopharma shares?

Yes, Indians can invest in the Arbutus Biopharma (ABUS) from India.

With INDmoney, you can buy Arbutus Biopharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Arbutus Biopharma at zero transaction cost.

How can I buy Arbutus Biopharma shares from India?

It is very easy to buy Arbutus Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arbutus Biopharma be purchased?

Yes, you can buy fractional shares of Arbutus Biopharma with INDmoney app.

What are the documents required to start investing in Arbutus Biopharma stocks?

To start investing in Arbutus Biopharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.